Creatinine

Summary

Creatinine (CHEMBL65567) is an approved small-molecule diagnostic agent; indicated across 1 condition including amyotrophic lateral sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 26
• Chemistry: 113.12 Da · C4H7N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL65567
Name	Creatinine
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	588
ChEBI	CHEBI:16737
Molecular formula	C4H7N3O
Molecular weight	113.12
InChIKey	DDRJAANPRJIHGJ-UHFFFAOYSA-N

SMILES: CN1CC(=O)N=C1N

IUPAC name: 2-amino-3-methyl-4H-imidazol-5-one

ChEBI definition: A lactam obtained by formal cyclocondensation of creatine. It is a metabolite of creatine.

Pharmacological roles (ChEBI): diagnostic agent.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Creatinine, Kreatininum, NSC-13123, creatinine, SID26749779, SID50085985, CREATININE, SID170466777, SID144205069

Parent form; salt/anhydrous children: CHEMBL1518203

Patent coverage: 45,904 distinct patent families (130,456 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 129,968 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Histone-lysine N-methyltransferase 2A.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976

Clinical trials

Total trials: 26.

Phase distribution

Phase	Trials
Not specified	23
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00005766	PHASE2	COMPLETED	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
NCT02280070	PHASE2	UNKNOWN	RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
NCT05105009	PHASE1	COMPLETED	Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
NCT06387667	Not specified	NOT_YET_RECRUITING	Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
NCT06463964	Not specified	ENROLLING_BY_INVITATION	Predictors of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure in Emergency
NCT06543927	Not specified	NOT_YET_RECRUITING	Frequency and Risk Factors of Bleeding in Patients With Chronic Kidney Disease Receiving Anticoagulants
NCT07195747	Not specified	NOT_YET_RECRUITING	Effects of Surgical, Percutaneous or Medical Treatments for Coronary Artery Disease on Renal Function: Long-Term Outcome. Cardiorenal-trial.
NCT07569588	Not specified	RECRUITING	Improving Patient Assessment After Acute Kidney Injury (AKI)
NCT01838265	Not specified	WITHDRAWN	Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management
NCT02111148	Not specified	UNKNOWN	Vaginal Fluid Wash in Pre-labour Rupture of Membranes
NCT02806089	Not specified	COMPLETED	Determinants of Muscle Strength in Chronic Kidney Disease
NCT03369561	Not specified	UNKNOWN	Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for Aki in Critical Care Patients
NCT03496246	Not specified	UNKNOWN	Vitamin D Status in Inflammatory Bowel Disease
NCT03658317	Not specified	UNKNOWN	Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
NCT03811860	Not specified	UNKNOWN	Lithium Therapeutic Drug Monitoring; Once Daily Vs Twice Daily Dosing and the Impact of Kidney Function
NCT04341974	Not specified	COMPLETED	Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury
NCT05102851	Not specified	COMPLETED	Impact of Prediabetes on Acute Coronary Syndrome
NCT05118074	Not specified	COMPLETED	Nova Max Creatinine and eGFR Meter System
NCT05144971	Not specified	COMPLETED	StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
NCT05214872	Not specified	COMPLETED	The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
NCT05321095	Not specified	COMPLETED	Screening for Albuminuria at the First Line for Early Identification of CKD
NCT05451472	Not specified	UNKNOWN	Evluation of Thyroid Functions in Hemodialysis Childern in Sohag University Hospital
NCT05691127	Not specified	UNKNOWN	Burden of Respiratory Illnesses in Pediatric Intensive Care Unit and Its Outcome
NCT05695573	Not specified	COMPLETED	Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy
NCT05867459	Not specified	UNKNOWN	Maternal and Fetal Outcome of CKD Mother Patient in Sohag Governorate
NCT06343389	Not specified	COMPLETED	Acute Kidney Injury in Patients With Liver Cirrhosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).